PhilHealth launches new benefits for post-kidney transplant

Chronic kidney disease (CKD) has emerged as a major health challenge in the Philippines, affecting as many as one in every three Filipinos. Its treatment often carries steep financial burdens that impact a patient’s employment, quality of life, and long-term stability. In response, the Philippine Health Insurance Corporation (PhilHealth) is expanding its coverage to ease the cost of care for patients living with or recovering from kidney-related conditions.

On Thursday, 19 June, PhilHealth launched its newest initiative: the "Z Benefits Package for Post-Kidney Transplantation Services." This aims to provide comprehensive support to Filipino patients, both children and adults, who have received kidney transplants. The expanded benefit package is designed not just to support the surgery itself but to ensure the long-term success of the transplant through sustained care, medication, and regular monitoring.

Under the new package, children who have undergone kidney transplants will receive coverage for their monthly immunosuppressive medications, with PhilHealth paying P73,065 per month during the first year and P41,150 in subsequent years. Additional benefits include up to P45,570 per month for drug prophylaxis or antibiotics to prevent infection, as well as quarterly laboratory test reimbursements — P37,585 per three months in the first year, and P14,078 in the following years.

Adults aged 19 and above are also entitled to significant support. PhilHealth will cover P40,725 monthly for immunosuppressive medications, along with P18,932 for a six-month supply of prophylactic treatment. In terms of laboratory testing, the state insurer will pay P11,242 every three months for the first year and P8,125 for the next year.

In 2024 alone, PhilHealth paid more than P28 billion for over five million hemodialysis claims nationwide. From 1 January to 31 May of this year, the agency has already disbursed P118.87 billion in total claims — a striking 84 percent increase compared to the same period in 2023.